MetricSide LogoMetricSide
Learn
  1. Home
  2. Companies
  3. Healthcare
  4. ANGO
OverviewMetricsPricesRevenue & ProfitAssets & LiabilitiesCash FlowMarginsPrice RatiosOthers
MetricSide

Standardized stock fundamentals and valuation metrics. Analyze revenue, EBITDA, free cash flow, and more with interactive charts.

Stock Sectors

  • Technology
  • Healthcare
  • Financials
  • Consumer
  • Industrials
  • Energy
  • Real Estate
  • Materials

Legal & Contact

  • Terms of Service
  • Privacy Policy
  • Contact Us
Not Financial Advice: MetricSide is a data aggregation and visualization tool. Nothing on this website constitutes investment advice, a recommendation, or a solicitation to buy or sell any security. All data is provided for informational and educational purposes only. Past performance is not indicative of future results. Always consult a qualified financial professional before making investment decisions. Data accuracy is not guaranteed — verify critical information against official sources.

© 2026 MetricSide. All rights reserved.

AngioDynamics (ANGO) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

AngioDynamics
NasdaqGS•Healthcare•Medical Instruments & Supplies
$15.06-0.26(-0.02%)Market open
Market Cap
$645.25M
P/S
2.0x
P/B
3.8x

AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells products for the treatment of cardiovascular disease and cancer diagnoses in the United States and internationally. The company operates through Med Tech and Med Device segments. It offers Auryon Atherectomy system that delivers an optimized wavelength and short pulse width to remove lesions while preserving vessel wall endothelium. The company's thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit for use in extracorporeal circulatory support procedures for periods of up to six hours, as well as with other manufacturers' off-the-shelf pump, filter, and reinfusion cannula facilitate venous drainage. It also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which include angiographic catheters, guidewires, drainage catheters, and micropuncture kits for use in invasive procedures. In addition, the company provides total abscession drainage catheters for multi-purpose/general and biliary configurations, and nephrostomy options; mini stick MAX Coaxial microintroducer kits and micro-introducer kits; ports; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero Microwave Tissue Ablation System includes solero microwave generator and the solero MW applicators. AngioDynamics, Inc. was founded in 1988 and is headquartered in Latham, New York.

C

How this company scores

AverageMetricSide Score: 50/100

Strongest: Balance Sheet & Red Flags (15/25); weakest: Profitability (9/25).

Profitability9/25
Growth13/25
Balance Sheet & Red Flags15/25
Cash & Earnings Quality13/25
Strengths
Interest easily coveredConsistent growthNet cash positionImproving margins

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 52.0x5y range 52.0x – 52.0x
P/E 52.0x
P/S · 2.0x5y range 0.7x – 3.7x
P/S 2.0x · above its 20-quarter median

Currently above its 20-quarter median.

P/B · 3.8x5y range 0.7x – 3.8x
P/B 3.8x · above its 20-quarter median

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 4 of the last 8 quarters — earnings are not translating to cash.

Price & Volume
Market Cap $645.25M

Metrics at a Glance

as of May 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue
$320.17M
5Q
Q. Revenue
$86.61M
8%
TTM EBITDA
$-16.97M
2Q
TTM Op. Income
$-39.93M
2Q
Q. Op. Income
$-10.20M
76%
TTM Net Income
$-36.74M
2Q
Q. Net Income
$-11.40M
2Q
EPS
$-0.273
2Q
Shares Out.
$41.79M
5Q
$320.17M in TTM revenue grew 9.5% YoY, reaching $86.61M last quarter. TTM EBITDA of $-16.97M and TTM operating income of $-39.93M show growth is flowing through to the bottom line. However, net income is negative at $36.74M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has risen for 5 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin
54.0%
3%
EBITDA Margin
-5.3%
9557%
Op. Margin
-11.8%
63%
Net Margin
-13.2%
2Q
Op. margin of -11.8% is down 4.6% YoY — costs are rising relative to revenue. Net margin at -13.2% and gross margin of 54.0% show how much of each revenue dollar survives to profit. Over the past year, operating margin is down 63% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio
N/A
P/S Ratio
2.0x
41%
P/B Ratio
3.8x
65%
P/S of 2.0x and P/B of 3.8x.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets
$267.16M
5%
Cash
$53.86M
4%
Long-Term Debt
N/A
Book Value
$170.82M
7Q
D/E Ratio
N/A
Debt/EBITDA
N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow
$17.45M
7%
TTM Free Cash Flow
$508,000
103%
FCF Margin
0.2%
103%
FCF / Net Income
-0.0
103%
TTM FCF of $508,000 on $17.45M in operating cash flow. The FCF / Net Income ratio of -0.0x means the business consumes cash — it is not yet self-funding. Over the past year, free cash flow is up 103% — a weakening trend.

Related Stocks in Healthcare

View Sector
LLY$938.28B
Lilly (Eli)
Drug Manufacturers - General
JNJ$586.47B
Johnson & Johnson
Drug Manufacturers - General
ABBV$411.57B
AbbVie
Drug Manufacturers - General
MRK$303.29B
Merck & Co.
Drug Manufacturers - General
UNH$249.74B
UnitedHealth Group
Healthcare Plans
TMO$203.77B
Thermo Fisher Scientific
Diagnostics & Research
AMGN$201.34B
Amgen
Drug Manufacturers - General
GILD$191.61B
Gilead Sciences
Drug Manufacturers - General

Currently above its 20-quarter median.

Cash Burn

Watch

4 of the last 8 quarters had negative FCF — inconsistent cash generation raises sustainability concerns.

Share Dilution

Watch

Shares outstanding rose 2.8% — mild dilution. Compare to earnings growth to assess the net per-share impact.